Kashyap et al. demonstrated that KDM1A directly regulates VEGFA expression in prostate cancer cells [44], suggesting that the anti-angiogenic effects observed in the tumor xenografts may be occurring via KDM1A inhibition of VEGFA expression resulting from NCL-1 treatment. This evidence concerns the gene CAPN3 and neoplasm.